Alumis Inc. (ALMS)

Alumis trailed consensus on both EPS and revenue in the second fiscal quarter of 2026, reported August 13, 2026, as revenue fell 38% to about $1.7 million (down from roughly $2.7 million a year ago) while EPS of -$1.11 trailed the -$0.77 estimate by -$0.34 and revenue of $1.7 million trailed the $3.7 million estimate (-54%). With gross profit also around $1.7 million, the quarter’s results still centered on a sizable expense base for its autoimmune-disorder pipeline, driving operating income to negative roughly $148.9 million and net income to negative about $142.2 million, versus net income of roughly $59.3 million a year ago. Consensus for the next period calls for EPS of -$0.73 on revenue of $1.9 million.